Literature DB >> 19067475

Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.

E E M Brouwers1, M Söhne, S Kuipers, E C M van Gorp, J H M Schellens, C H W Koks, J H Beijnen, A D R Huitema.   

Abstract

We report on two cases of drug-drug interactions between ciprofloxacin and clozapine. The first case was a 46-year-old male patient receiving a daily dose of clozapine 900 mg. He was admitted to hospital with urosepsis and was treated with a 5-day course of ciprofloxacin and amoxicillin. Two days after completion of antibacterial therapy, the patient developed symptoms of rhabdomyolysis. Clozapine therapy was discontinued and measurement of the patient's clozapine plasma concentration 1 day after cessation of clozapine therapy and 3 days after cessation of ciprofloxacin treatment showed that it was in excess of recommended therapeutic levels. The second patient was a 58-year-old male patient treated with a daily dose of clozapine 300 mg. He was admitted to hospital because of delirium and suspected urinary tract infection or pneumonia. Treatment with ciprofloxacin was initiated. Measurement of clozapine plasma concentrations prior to and 3 days after commencement of ciprofloxacin showed that clozapine concentrations doubled over that time period. We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations. This might cause severe adverse effects. We advise using another antibacterial agent or reducing the clozapine dose and monitoring clozapine levels when this antipsychotic agent is used in combination with ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067475     DOI: 10.2165/0044011-200929010-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  17 in total

Review 1.  Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature.

Authors:  J L Karagianis; L C Phillips; K P Hogan; K K LeDrew
Journal:  Ann Pharmacother       Date:  1999-05       Impact factor: 3.154

2.  The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system.

Authors:  Tara E Nicholson; Kenneth W Renton
Journal:  Drug Metab Dispos       Date:  2002-01       Impact factor: 3.922

3.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

4.  Interaction of clozapine and ciprofloxacin: a case report.

Authors:  Rajvinder S Sambhi; Ramneesh Puri; Gaynor Jones
Journal:  Eur J Clin Pharmacol       Date:  2007-07-12       Impact factor: 2.953

5.  Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia.

Authors:  K Raaska; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2000-11       Impact factor: 2.953

6.  Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.

Authors:  Marika T Granfors; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

7.  Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.

Authors:  H Y Meltzer; P A Cola; M Parsa
Journal:  Neuropsychopharmacology       Date:  1996-10       Impact factor: 7.853

Review 8.  Clozapine: a clinical review of adverse effects and management.

Authors:  Mohammad Masud Iqbal; Atiq Rahman; Zahid Husain; Syed Zaber Mahmud; Wlliam G Ryan; Jacqueline M Feldman
Journal:  Ann Clin Psychiatry       Date:  2003-03       Impact factor: 1.567

Review 9.  Pain insensitivity in schizophrenia: a neglected phenomenon and some implications.

Authors:  R H Dworkin
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

Review 10.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

View more
  10 in total

Review 1.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 2.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 3.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

4.  Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction.

Authors:  Jonathan M Meyer; George Proctor; Michael A Cummings; Laura J Dardashti; Stephen M Stahl
Journal:  Case Rep Psychiatry       Date:  2016-10-30

5.  Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals.

Authors:  R J Flanagan; J Lally; S Gee; R Lyon; S Every-Palmer
Journal:  Br Med Bull       Date:  2020-10-14       Impact factor: 4.291

Review 6.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

7.  Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.

Authors:  Laurent Béchard; Olivier Corbeil; Marc-André Thivierge; Ibrahim Assaad; Camille Boulanger; Marie-Pierre Mailhot; Alexis Turgeon-Fournier; Marc-André Roy; Marie-France Demers
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

8.  Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin.

Authors:  Martin Šíma; Daniel Bobek; Petra Cihlářová; Pavel Ryšánek; Jaroslava Roušarová; Jan Beroušek; Martin Kuchař; Tomáš Vymazal; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2022-08-04       Impact factor: 6.525

Review 9.  Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review.

Authors:  Kazuaki Sasaki; Minoru Shimoda
Journal:  J Adv Res       Date:  2015-02-24       Impact factor: 10.479

Review 10.  Use of Clozapine in the General Hospital.

Authors:  Feras Ali Mustafa
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.